

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 Or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2018

**GT Biopharma, Inc.**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other Jurisdiction of Incorporation or  
organization)

**000-08092**  
(Commission File Number)

**94-1620407**  
(IRS Employer I.D. No.)

---

**310 N. Westlake Blvd  
Suite 206  
Westlake Village, CA 91362  
Phone: (800) 304-9888**

(Address, including zip code, and telephone number, including area code, of  
registrant's principal executive offices)

**100 South Ashley Drive  
Suite 600  
Tampa, FL 33602**

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 11, 2018, Steven Weldon resigned from the Board. Mr. Weldon also resigned from his position as Chief Financial Officer at GT Biopharma. This resignation was also effective as of October 11, 2018. Neither resignation involved any disagreement with the Company.

**SIGNATURE PAGE**

Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GT Biopharma, Inc.**

Dated: October 16, 2018

By: /s/Raymond W Urbanski  
Raymond W. Urbanski  
Chairman and Chief Executive Officer